A型肉毒毒素治疗儿童偏头痛的随机双盲安慰剂对照交叉研究
本研究纳入8至17岁慢性偏头痛患儿,采用随机双盲安慰剂对照交叉设计,评估A型肉毒毒素(OBTA)与安慰剂在随访时的疗效差异。结果显示OBTA在偏头痛频率、强度和PedMIDAS评分上较基线有统计学显著下降,但持续时间无显著差异,未报告相关不良事件。
要点
- OBTA可显著降低儿童偏头痛频率和强度,但持续时间无显著改善。
- 研究未报告与OBTA相关的不良事件或严重不良事件。
- 样本量较小,结论需更大规模研究验证。
核心结论
- 与安慰剂相比,OBTA在治疗6周后使儿童偏头痛频率、强度和PedMIDAS评分较基线有统计学显著下降,但持续时间无显著差异。
研究设计与样本
- 随机双盲安慰剂对照交叉试验,纳入8至17岁慢性偏头痛患儿,最终15例符合标准。
主要发现
- OBTA组频率较基线下降:20(7至17) vs 安慰剂28(23至28),p=0.038。
- OBTA组强度较基线下降:5(3至7) vs 安慰剂7(5至9),p=0.047。
- OBTA组PedMIDAS较基线下降:3(2至4) vs 安慰剂4(4至4),p=0.047。
- 持续时间无显著差异:10(2至24) vs 24(4至24),p=0.148。
- 未报告与OBTA相关的不良事件或严重不良事件。
临床怎么用
- 对于8至17岁慢性偏头痛患儿,OBTA可能改善频率和强度,但需注意样本量小且持续时间未获益。
局限性
- 样本量小(15例),结论需更大规模研究验证。
- 研究未评估偏头痛特征(如疼痛性质/位置)对疗效的预测作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: OnabotulinumtoxinA (OBTA) is approved for treating chronic headaches and migraines in adults, but there is limited scientific literature on the outcomes in pediatric patients. The aim of this study was to determine if subjects treated with OBTA reported a statistically significant improvement in the primary features (frequency, intensity, duration and disability scoring) associated with migraines compared with placebo at follow-up visits. METHODS: After obtaining approval by the appropriate local (HS# 2016-3108) and federal institutions, the principal investigator enrolled candidates aged 8 to 17 years old diagnosed with chronic migraines (at least 6 months), and 15 or more headache days in a 4-week baseline period. This randomized control trial consisted of two phases: double-blind and open-label for the first two and last two sets of treatments, respectively. Subjects were randomly assigned to receive a treatment protocol-155 units at 31 injection sites-in 3-month intervals and follow-up visits every 6 weeks. Non-parametric testing (Wilcoxon signed-rank test) was performed using widely available open-source statistical software ('R'). RESULTS: From February 2017 to November 2018, 17 subjects presented for a screening visit; 15 met eligibility criteria. Subjects that received OBTA reported a statistically significant decrease from the following baseline values compared with placebo 6-week post-treatment compared with placebo: frequency (20 (7 to 17) vs 28 (23 to 28); p=0.038), intensity (5 (3 to 7) vs 7 (5 to 9); p=0.047), and PedMIDAS (Pediatric Migraine Disability Score) (3 (2 to 4) vs 4 (4 to 4); p=0.047). There was no statistically significant difference in the duration (10 (2 to 24) vs 24 (4 to 24); p=0.148) of migraines between the two groups. DISCUSSION: OnabotulinumtoxinA showed a statistically significant decrease in frequency and intensity of migraines compared with placebo. No adverse effects or serious adverse events related to the use of OBTA were reported. In the future, we aim to evaluate the specific nature of migraines, for example, quality/location of pain presented during an initial consult to predict the likelihood of OBTA being a truly effective modality of pain management for pediatric migraineurs. TRIAL REGISTRATION NUMBER: NCT03055767.
引用
- Shah S, Calderon MD, Crain N, et al. Effectiveness of onabotulinumtoxinA (BOTOX) in pediatric patients experiencing migraines: a randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population. Reg Anesth Pain Med. 2020. PMID: 33106278. doi:10.1136/rapm-2020-101605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。